610
Participants
Start Date
April 24, 2015
Primary Completion Date
November 22, 2019
Study Completion Date
November 22, 2019
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
Atezolizumab will be administered intravenously.
MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
MOXR0916 will be administered intravenously.
Institut Jules Bordet, Anderlecht
Chris O'Brien Lifehouse, Camperdown
Sint Augustinus Wilrijk, Wilrijk
Peter Maccallum Cancer Centre, Melbourne
Austin Hospital, Heidelberg
Sir Charles Gairdner Hospital, Nedlands
UZ Gent, Ghent
Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.
Hosp de Madrid Norte Sanchinarro; Centro Integral; Onco Clara Campal, Madrid
Clinica Universitaria de Navarra, Pamplona
Sarah Cannon Research Institute, Nashville
Hospital Clinico Universitario de Valencia, Valencia
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago
HonorHealth Research Institute - Bisgrove, Scottsdale
Gustave Roussy, Villejuif
Seattle Cancer Care Alliance, Seattle
University of Colorado, Aurora
Yale School of Medicine, New Haven
Beth Israel Deaconess Medical Center, Boston
Dana Farber Can Ins, Boston
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Yonsei University Health System/Severance Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY